ANIXA Biosciences Inc

At the H.C. Wainwright conference, Anixa Biosciences presented positive early data for its CAR‑T program in ovarian cancer (14 patients treated; one survived 28 months, several >1 year vs expected ~12 weeks) and for a breast cancer vaccine that completed phase I with 35 patients and showed immune responses in ~75%. The company has $14M in cash, an annual burn rate of $5–7M, is debt‑free, and plans to out‑license both programs to partners after clinical success rather than build a large commercial infrastructure. Next clinical steps are dose escalation for the CAR‑T and moving the vaccine into phase II with a randomized neoadjuvant design. » Więcej na de.investing.com

Anixa has treated the first patient in the fifth cohort of its Phase 1 study at Moffitt Cancer Center with 1×10^7 CAR‑positive cells/kg, the highest dose level tested to date. No dose‑limiting toxicities were observed at the previous dose level (3×10^6/kg). The Lira‑Cel therapy targets the follicle‑stimulating hormone receptor and has shown long‑term survival of up to more than two years in some patients. The stock recently rose 14.7% to $3.27, with a market capitalization of $111 million. » Więcej na de.investing.com

The Korean Intellectual Property Office granted Anixa the patent (No. 10-2960889) for its breast cancer vaccine technology, providing protection in South Korea until 2040. The technology, exclusively licensed from the Cleveland Clinic, aims at prevention and treatment by immunization against human α-Lactalbumin. A phase‑1 study met all primary endpoints, was safe, well tolerated and showed an immune response in 74% of participants. Anixa remains clinically unbalanced but has more liquid assets than debt; analysts see price targets of $7–14 versus the current level of about $2.79. » Więcej na de.investing.com